Chicago Equity Partners LLC Has $2.15 Million Stake in Portola Pharmaceuticals, Inc. (PTLA)

Chicago Equity Partners LLC raised its holdings in shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) by 605.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 39,839 shares of the biopharmaceutical company’s stock after acquiring an additional 34,194 shares during the quarter. Chicago Equity Partners LLC owned approximately 0.06% of Portola Pharmaceuticals worth $2,153,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Kornitzer Capital Management Inc. KS boosted its position in shares of Portola Pharmaceuticals by 38.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock valued at $39,324,000 after purchasing an additional 202,925 shares during the period. Emerald Mutual Fund Advisers Trust boosted its position in shares of Portola Pharmaceuticals by 3.4% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 374,908 shares of the biopharmaceutical company’s stock valued at $20,256,000 after purchasing an additional 12,197 shares during the period. Emerald Advisers Inc. PA boosted its position in shares of Portola Pharmaceuticals by 2.2% in the 3rd quarter. Emerald Advisers Inc. PA now owns 453,921 shares of the biopharmaceutical company’s stock valued at $24,525,000 after purchasing an additional 9,703 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Portola Pharmaceuticals in the 3rd quarter valued at about $178,000. Finally, Rosenblum Silverman Sutton S F Inc. CA boosted its position in shares of Portola Pharmaceuticals by 21.3% in the 3rd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 129,330 shares of the biopharmaceutical company’s stock valued at $6,988,000 after purchasing an additional 22,710 shares during the period. 86.04% of the stock is owned by institutional investors and hedge funds.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) opened at $48.95 on Monday. Portola Pharmaceuticals, Inc. has a one year low of $17.15 and a one year high of $67.10. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.08. The firm had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. Portola Pharmaceuticals’s quarterly revenue was down 58.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.64) EPS. equities analysts anticipate that Portola Pharmaceuticals, Inc. will post -4.95 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Chicago Equity Partners LLC Has $2.15 Million Stake in Portola Pharmaceuticals, Inc. (PTLA)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/11/13/chicago-equity-partners-llc-has-2-15-million-stake-in-portola-pharmaceuticals-inc-ptla.html.

A number of analysts have weighed in on PTLA shares. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $80.00 price objective on shares of Portola Pharmaceuticals in a research report on Wednesday, September 6th. Zacks Investment Research cut Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. BidaskClub cut Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 19th. Morgan Stanley reaffirmed an “overweight” rating and set a $81.00 price objective (up from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. Finally, Credit Suisse Group raised Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price objective for the company in a research report on Wednesday, August 23rd. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $65.15.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply